BAY 1142524

Drug Profile

BAY 1142524

Alternative Names: BAY1142524

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Bayer HealthCare
  • Class Heart failure therapies
  • Mechanism of Action Chymase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Left ventricular dysfunction

Most Recent Events

  • 30 Sep 2016 Phase-II clinical trials in Left ventricular dysfunction (Adjunctive treatment) in Spain (PO) (EudraCT2016-002167-33)
  • 01 Mar 2016 Bayer completes the CHIARA MIA 1 trial in Left ventricular dysfunction (Adjunctive treatment) in Denmark, Germany and Italy (PO) (NCT02452515)
  • 06 Jul 2015 Phase-II clinical trials in Left ventricular dysfunction (Adjunctive treatment) in Italy and Germany (PO) (NCT02452515)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top